Nektar Phase II Study: Anti-tumor activity in 7/18 evaluable patients with solid tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Nektar Therapeutics announced that new phase I clinical data for Nektar’s lead immuno-oncology agent, NKTR-214, were presented at the SITC 2016 Annual Meeting.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login